CHF

Randomized trial suggests benefit is largely in those with 40-60% ejection fraction

But procedure no less effective for this higher risk group, COAPT trial post hoc analysis shows

Benefits similar across anatomical complexity, advanced heart failure in post-marketing studies

Future treatments don't have to be limited to slowing disease, case series suggests

SGLT1/SGLT2 inhibitor approved on the basis of SOLOIST-WHF, SCORED trials

6-month follow-up with investigational device gives support for pivotal trial

Study underscores importance of anatomical, physiological parameters

SPRINT post hoc analysis suggests a means for prevention

An updated meta-analysis of the controversial practice shows no definite answers

Choose the first procedure wisely, because repeats have mortality implications, researchers say

Research suggests cancer-specific precision monitoring and risk stratification

If finerenone isn't available, try spironolactone, said researcher

Consider adding a potassium binder to the mix, researcher suggests

Cardiovascular devices lead the pack in having multiple iterations culminate in device recall